Published 3 days ago • loading... • Updated 2 days ago

Biogen continues dealmaking buzz with Stoke Therapeutics

Summary by The Business Journals

Biogen Inc. is making good on its promise to focus on “external opportunities,” this time with a new deal involving a Bedford-based biotech.

8 Articles

All

Left

Center

Right

The Business Journals

Biogen continues dealmaking buzz with Stoke Therapeutics

Biogen Inc. is making good on its promise to focus on “external opportunities,” this time with a new deal involving a Bedford-based biotech.

3 days ago·United States

Read Full Article

STAT

Biogen partners with Stoke Therapeutics to sell severe epilepsy drug

Today's biotech news includes Biogen partnering with Stoke Therapeutics, the medical ethics of abruptly canceling USAID trials, and more.

3 days ago·Boston, United States

Read Full Article

biopharmadive.com

Biogen buys rights to Stoke’s rare epilepsy drug

In exchange for $165 million, Biogen now has access to zorevunersen, a potential first-of-its-kind treatment for Dravet syndrome.

3 days ago

Read Full Article

Pharmaphorum

Biogen bags rights to epilepsy drug from Stoke in $550m deal

Biogen has bolstered its pipeline by licensing ex-US rights to a drug for Dravet syndrome – a rare form of epilepsy – from Stoke Therapeutics

2 days ago

Read Full Article

pharmaceutical-technology.com

Biogen and Stoke to commercialise Dravet syndrome treatment

Biogen has entered a collaboration with Stoke Therapeutics to develop and commercialise zorevunersen to treat Dravet syndrome.

2 days ago

Read Full Article

BizToc

Biogen Strengthens Pipeline With Stoke Therapeutic's Dravet Syndrome Candidate Via Multi-Million Dollar Deal

On Tuesday, Biogen Inc. (NASDAQ:BIIB) and Stoke Therapeutics, Inc. (NASDAQ:STOK) collaborated to develop and commercialize zorevunersen for Dravet syndrome in all territories outside the United States, Canada, and Mexico. Zorevunersen is an investigational antisense oligonucleotide (ASO) that…

3 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year